^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RC108

    i
    Other names: RC108, RC108-ADC
    Associations

    News

    Trials
    Company:
    Rongchang Pharma
    Drug class:
    Microtubule inhibitor, c-MET-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    5ms
    RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (clinicaltrials.gov)
    P1/2, N=106, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation
    |
    Loqtorzi (toripalimab-tpzi) • Ivesa (furmonertinib) • RC108
    1year
    RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC (clinicaltrials.gov)
    P1/2, N=106, Not yet recruiting, RemeGen Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression • EGFR exon 18 mutation
    |
    Loqtorzi (toripalimab-tpzi) • Ivesa (furmonertinib) • RC108
    1year
    A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov)
    P2, N=240, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET positive
    |
    RC108
    over1year
    A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, RemeGen Co., Ltd.
    New P2 trial • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET positive
    |
    RC108
    3years
    A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=32, Recruiting, RemeGen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET positive
    |
    RC108
    over3years
    A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, RemeGen
    Clinical • New P1 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET positive
    |
    RC108